--- title: "OnKure Therapeutics (OKUR) news: offering and merger" url: "https://aibio.space/companies/onkure-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "OKUR offering and merger news: OnKure files $100,000,000 at-the-market stock sale supplement. OnKure Therapeutics, Inc. (NASDAQ: OKUR), United States." --- OKUR OnKure Therapeutics, Inc. NASDAQ · United States # OnKure Therapeutics (OKUR) news OKUR offering and merger news Legal · 2026-08-04 ## [OnKure says plaintiffs have not pursued two New York suits over its Reneo merger proxy](https://aibio.space/news/onkure-says-plaintiffs-have-not-pursued-two-new-york-suits-reneo/) Thomas and Kent v. Reneo name Reneo and unnamed individual defendants. The 10-Q says plaintiffs have not pursued the claims; the 2024 proxy lists Reneo's board. ## Latest OnKure Therapeutics news 1. 2026-08-04 Financings [OnKure files $100,000,000 at-the-market stock sale supplement](https://aibio.space/news/onkure-files-100-000-000-market-stock-sale-supplement/) The company says it is no longer subject to a Form S-3 sales limit. It had not sold any Class A shares under the program as of August 4, 2026. 2. 2026-06-04 Listings [OnKure Therapeutics holders approve equity plan adding 3,231,638 shares](https://aibio.space/news/onkure-therapeutics-holders-approve-equity-plan-adding-3-231-638/) The amended 2024 plan also drops a cap on its annual share increase. The vote came at the June 3, 2026 annual meeting. 3. 2026-03-30 Financings [OnKure Therapeutics agrees to $150.0 million private placement at $4.15 per share](https://aibio.space/news/onkure-therapeutics-agrees-150-0-million-private-placement-4-15-share/) OnKure Therapeutics, Inc. is selling 26,713,636 shares and pre-funded warrants for 9,430,959 shares to institutional accredited investors. AI Biotechnology LLC is lead investor and gets a board nominee right. ## OnKure Therapeutics at a glance - **Ticker**: OKUR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $176.4 million ### Related companies - [Viridian Therapeutics](https://aibio.space/companies/viridian-therapeutics/) NASDAQ: VRDN - [Madrigal Pharmaceuticals](https://aibio.space/companies/madrigal-pharmaceuticals/) NASDAQ: MDGL - [Keros Therapeutics](https://aibio.space/companies/keros-therapeutics/) NASDAQ: KROS - [Harmony Biosciences Holdings](https://aibio.space/companies/harmony-biosciences/) NASDAQ: HRMY - [Kairos Pharma](https://aibio.space/companies/kairos-pharma/) AMEX: KAPA - [Inhibitor Therapeutics](https://aibio.space/companies/inhibitor-therapeutics/) OTC: INTI - [Biofrontera](https://aibio.space/companies/biofrontera-bfri/) NASDAQ: BFRI - [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) NASDAQ: ANTX ### Also on NASDAQ - [ADMA Biologics](https://aibio.space/companies/adma-biologics/) ADMA - [Attovia Therapeutics](https://aibio.space/companies/attovia-therapeutics/) ATTO - [Cytosorbents](https://aibio.space/companies/cytosorbents/) CTSO - [Evolus](https://aibio.space/companies/evolus/) EOLS - [MANNATECH INC](https://aibio.space/companies/mannatech/) MTEX - [Corvus Pharmaceuticals](https://aibio.space/companies/corvus-pharmaceuticals/) CRVS ## What OnKure Therapeutics does OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines that target biologically validated drivers of cancers and other diseases underserved by available therapies. It uses a structure-based drug design platform to build small molecule drugs that selectively target mutated forms of proteins. Its lead product candidate, OKI-219, is a highly selective inhibitor of PI3Kα harboring the H1047R mutation, with approximately 80-fold selectivity for the mutated form over the wild-type enzyme. The company plans to initially focus OKI-219 on advanced breast cancer in genetic subtypes that are hormone receptor positive and HER2 negative, and HER2 positive. OKI-219 is being investigated in the first-in-human Phase 1 open-label PIKture-01 trial in patients with solid tumors. Enrollment is complete in Part A, the monotherapy arm, and Part B, the fulvestrant combination arm, while Parts C and E are enrolling. | Product or program | What it is | Stage | |---|---|---| | OKI-219 | Highly selective inhibitor of mutant PI3Kα H1047R for advanced breast cancer | Phase 1 (PIKture-01) | Summarised from the company's [10-K filed Mar 12, 2026](https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/okur-20251231.htm). ## OnKure Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$0](https://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/) | | Research and development | [$48.3 million](https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/) | [$43.8 million](https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/) | | Net income (loss) | [-$59.5 million](https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/) | [-$52.7 million](https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/) | | Cash from operations | [-$51.8 million](https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/) | [-$51.1 million](https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/) | | Cash and equivalents | [$59.0 million](https://www.sec.gov/Archives/edgar/data/1637715/000119312526332773/) | [$110.8 million](https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/) | | Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/1637715/000119312526332773/) | | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $166.5 million, plus short-term investments of $9.9 million, $176.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about OnKure Therapeutics Has OnKure Therapeutics raised money recently? Our latest story on this, dated Aug 4, 2026: "OnKure files $100,000,000 at-the-market stock sale supplement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/onkure-files-100-000-000-market-stock-sale-supplement/). Is OnKure Therapeutics involved in a merger or acquisition? Our latest story on this, dated Aug 4, 2026: "OnKure says plaintiffs have not pursued two New York suits over its Reneo merger proxy". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/onkure-says-plaintiffs-have-not-pursued-two-new-york-suits-reneo/). What is the ticker symbol of OnKure Therapeutics? OnKure Therapeutics, Inc. trades under the ticker OKUR on NASDAQ. Where is OnKure Therapeutics listed? OnKure Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of OnKure Therapeutics? The SEC Central Index Key (CIK) for OnKure Therapeutics, Inc. is 1637715. Its filings are on SEC EDGAR. How many shares does OnKure Therapeutics have outstanding? 40,496,309 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is OnKure Therapeutics listed under? Our directory records OnKure Therapeutics, Inc. under United States. What does OnKure Therapeutics do? Our directory classifies OnKure Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of OnKure Therapeutics? The ISIN recorded for OnKure Therapeutics, Inc. is US68277Q1058. Does aibio.space cover OnKure Therapeutics? aibio.space lists OnKure Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is OnKure Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does OnKure Therapeutics develop? OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines that target biologically validated drivers of cancers and other diseases underserved by available therapies. It uses a structure-based drug design platform to build small molecule drugs that selectively target mutated forms of proteins. What is OKI-219 from OnKure Therapeutics? OKI-219: Highly selective inhibitor of mutant PI3Kα H1047R for advanced breast cancer Stage: Phase 1 (PIKture-01). Is OnKure Therapeutics profitable? OnKure Therapeutics, Inc. reported a net loss of $59.5 million for the fiscal year ended Dec 31, 2025, and used $51.8 million of cash in operations, per its annual report to the SEC. How much does OnKure Therapeutics spend on research and development? $48.3 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: OnKure Therapeutics Members talk about OnKure Therapeutics (OKUR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at OnKure Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-04 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1637715/000119312526332839/okur_424b5-20260804.htm) 2. 2026-06-04 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/okur-20260603.htm) 3. 2026-03-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/d910791d8k.htm) 4. 2026-03-12 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/okur-20251231.htm) 5. 2025-11-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1637715/000119312525269652/okur-20251106.htm) 6. 2024-11-07 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1637715/000095017024123265/okur-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:OKUR on TradingView](https://www.tradingview.com/symbols/NASDAQ-OKUR/). ## SEC filings and registration - **SEC name**: OnKure Therapeutics, Inc. - **CIK**: 1637715 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: OKUR (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 6707 WINCHESTER CIRCLE, SUITE 400, BOULDER, CO, 80301 - **Phone**: (720) 307-2892 - **Shares outstanding**: 40,496,309 as of 2026-08-03 (10-Q filed 2026-08-04) - **Former names**: Reneo Pharmaceuticals, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1637715/000119312526347315/okur-20260807.htm) filed 2026-08-13 - [424B5](https://www.sec.gov/Archives/edgar/data/1637715/000119312526332839/okur_424b5-20260804.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1637715/000119312526332809/okur-20260804.htm) filed 2026-08-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1637715/000119312526332773/okur-20260630.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/okur-20260603.htm) filed 2026-06-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1637715/000119312526206396/okur-20260505.htm) filed 2026-05-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1637715/000119312526206345/okur-20260331.htm) filed 2026-05-05 - [S-3](https://www.sec.gov/Archives/edgar/data/1637715/000119312526177093/d122209ds3.htm) filed 2026-04-24 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001637715), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details OnKure Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker OKUR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: OnKure Therapeutics, Inc. - **Ticker**: OKUR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US68277Q1058 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-OKUR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/onkure-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "OnKure Therapeutics (OKUR) news: offering and merger", 2026-10-31, https://aibio.space/companies/onkure-therapeutics/